Loading
TH
Thorne Healthtech, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Varma Saloni S., was filed 24 Mar 2022.
Thorne Healthtech, Inc.: what insiders have been doing
Thorne Healthtech, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at Thorne Healthtech, Inc. has published a filing in the past twelve months. The most recent one dates from 18 October 2023.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
48
Thresholds
n/a
Buy Volume
€50,221
1 ops. · all time
Sell Volume
n/a
6 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$196.9M
Gross profitUS$99M50% margin
Net incomeUS$13.5M6.9% margin
Last declaration on 18 October 2023
Declarations48 total
59,907 shares@ US$4.7024.3% of flowCommon StockSEC:0001209191-23-053085:0
11,257 shares@ US$4.7015.8% of flowCommon StockSEC:0001209191-23-053088:0
45,338 shares@ US$4.7218.2% of flowCommon StockSEC:0001209191-23-053086:0
7,571 shares@ US$4.7226.6% of flowCommon StockSEC:0001209191-23-053087:0
3,454 shares@ US$4.7216.0% of flowCommon StockSEC:0001209191-23-053089:0
5,424,550 sharesCommon StockSEC:0001209191-23-053090:0
2,105,589 sharesCommon StockSEC:0001209191-23-053091:0
1,172,227 sharesCommon StockSEC:0001209191-23-053098:0
581,643 sharesCommon StockSEC:0001209191-23-053099:0
589,804 sharesCommon StockSEC:0001209191-23-053095:0
105,874 sharesCommon StockSEC:0001209191-23-053092:0
15,674,235 shares@ US$10.20100.0% of flowCommon StockSEC:0001104659-23-109580:0
15,674,235 sharesCommon StockSEC:0001209191-23-052958:0
220,377 shares0Common StockSEC:0001977249-23-000031:0
23,513 shares@ US$4.7232.7% of flowCommon StockSEC:0001209191-23-023655:0
6,430 shares@ US$4.7229.8% of flowCommon StockSEC:0001209191-23-023656:0
40,556 shares@ US$4.7216.3% of flowCommon StockSEC:0001209191-23-023652:0
7,609 shares@ US$4.7226.8% of flowCommon StockSEC:0001209191-23-023654:0
30,000 shares0Common StockSEC:0001209191-23-023653:0
52,619 shares@ US$4.7021.3% of flowCommon StockSEC:0001209191-23-021426:0
11,440 shares@ US$4.7016.0% of flowCommon StockSEC:0001209191-23-021428:0
12,175 shares@ US$4.8946.6% of flowCommon StockSEC:0001209191-22-059816:0
45,338 shares@ US$4.8919.9% of flowCommon StockSEC:0001209191-22-059811:0
23,513 shares@ US$4.8935.6% of flowCommon StockSEC:0001209191-22-059814:0
7,838 shares@ US$4.89100.0% of flowCommon StockSEC:0001209191-22-059818:0
25 of 48 declarations
About Thorne Healthtech, Inc.
Thorne HealthTech, Inc. is a United States-based health and wellness company listed on the NASDAQ under the ticker THRN. For investors, the company sits at the intersection of consumer health, preventive care, personalized nutrition, and data-enabled wellness solutions. Its business model combines branded supplements, practitioner-led distribution, testing capabilities, and science-driven products aimed at consumers, health professionals, and corporate wellness use cases. ([thorne.com](https://www.thorne.com/press-releases/thorne-merges-with-onegevity-announces-new-parent-company-thorne-healthtech%3Fsrsltid%3DAfmBOop9VXyjJhNdSo4EQQvaHB2Y0vWNqqkPPl7lvlEt3rOs6TpX0YsP?utm_source=openai))
Thorne says its roots date back to 1984, giving the brand a long operating history in nutritional supplements and wellness products. A key strategic milestone came in 2010, when Paul Jacobson and his team acquired Thorne Research. In 2018, the company co-founded Onegevity to broaden its capabilities into health intelligence, personalization, and multi-omic data. More recently, in December 2023, Thorne announced the launch of Thorne Ventures and a reorganization into two units: Thorne, focused on supplements and testing, and Thorne Ventures, focused on innovation and the next generation of scientific wellness. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1844280/000095017023011358/thrn-20221231.htm?utm_source=openai))
Read moreShow less
Operationally, Thorne develops and sells clinically informed nutritional supplements, daily wellness essentials, probiotics, digestive health products, immune support formulas, cognitive health products, and performance-oriented solutions. The company emphasizes ingredient quality, rigorous manufacturing standards, in-house laboratory testing, third-party certifications, and collaborations with clinical researchers. Its proposition is not just product breadth, but scientific credibility and a personalized approach to health optimization. ([thorne.com](https://www.thorne.com/?utm_source=openai))
Thorne’s competitive positioning is built around trust and practitioner influence. In its 2022 annual report, the company disclosed a network of more than 47,000 health professionals, including physicians, dietitians, pharmacists, chiropractors, nutritionists, trainers, and other accredited practitioners. That distribution model is significant in a crowded supplements market, where differentiation typically depends on clinical reputation, brand quality, formulation integrity, and the ability to convert professional endorsement into repeat demand. Thorne’s brand is therefore closer to a premium science-led platform than a mass-market commodity supplement seller. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1844280/000095017023011358/thrn-20221231.htm?utm_source=openai))
Geographically, the company is headquartered in New York, United States, and primarily operates in the U.S., while also serving international markets through selected channels. Recent strategic developments include the February 2023 acquisition of PreCon Health to strengthen its brain-health portfolio, earlier transactions involving Nutrativa and Drawbridge Health, and the completion of L Catterton’s acquisition of Thorne HealthTech in 2023. For investors monitoring SEC Form 4 insider transactions, Thorne remains notable as a NASDAQ-listed health-tech and consumer wellness company with a science-driven identity, a premium brand position, and a growth strategy shaped by innovation, data, and selective M&A. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001844280/000095017023001743/thrn-ex99_1.htm?utm_source=openai))
